In the past week, ZOM stock has gone down by -0.65%, with a monthly gain of 1.58% and a quarterly surge of 0.91%. The volatility ratio for the week is 1.97%, and the volatility levels for the last 30 days are 4.78% for Zomedica Corp The simple moving average for the past 20 days is -5.29% for ZOM’s stock, with a -11.41% simple moving average for the past 200 days.
Is It Worth Investing in Zomedica Corp (AMEX: ZOM) Right Now?
ZOM has 36-month beta value of 1.03. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZOM is 962.66M, and currently, short sellers hold a 4.66% ratio of that float. The average trading volume of ZOM on February 03, 2025 was 6.63M shares.
ZOM) stock’s latest price update
The stock of Zomedica Corp (AMEX: ZOM) has decreased by -0.81 when compared to last closing price of 0.12.Despite this, the company has seen a loss of -0.65% in its stock price over the last five trading days. accesswire.com reported 2025-01-07 that License Agreement Expands Zomedica’s Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States. Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.
Analysts’ Opinion of ZOM
Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the previous year 2023.
ZOM Trading at -3.78% from the 50-Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.55% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 1.97%, as shares sank -12.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.49% lower at present.
During the last 5 trading sessions, ZOM fell by -1.14%, which changed the moving average for the period of 200-days by -6.98% in comparison to the 20-day moving average, which settled at $0.1287. In addition, Zomedica Corp saw 1.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZOM starting from Blair Anthony K, who purchase 150,000 shares at the price of $0.12 back on Nov 08 ’24. After this action, Blair Anthony K now owns 400,000 shares of Zomedica Corp, valued at $18,450 using the latest closing price.
POWERS JOHNNY D, the Director of Zomedica Corp, purchase 100,000 shares at $0.12 during a trade that took place back on Nov 11 ’24, which means that POWERS JOHNNY D is holding 2,425,000 shares at $12,100 based on the most recent closing price.
Stock Fundamentals for ZOM
Current profitability levels for the company are sitting at:
- -1.43 for the present operating margin
- 0.55 for the gross margin
The net margin for Zomedica Corp stands at -2.33. The total capital return value is set at -0.19. Equity return is now at value -26.82, with -25.43 for asset returns.
Based on Zomedica Corp (ZOM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -11.47.
Currently, EBITDA for the company is -29.39 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.18. The receivables turnover for the company is 11.2for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.82.
Conclusion
To put it simply, Zomedica Corp (ZOM) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
